Status:
COMPLETED
Xalacom And Combination Of Unfixed Latanoprost And Timolol In Subjects With Open-Angle Glaucoma Or Ocular Hypertension
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Conditions:
Glaucoma, Open Angle
Ocular Hypertension
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
to compare efficacy and safety of Xalacom with the combination of unfixed Latanoprost and Timolol in subjects with open-angel glaucoma or ocular hypertension
Eligibility Criteria
Inclusion
- patients with open-angle glaucoma or ocular hypertension
Exclusion
- closed/barely open anterior chamber angle or a history of acute angel closure glaucoma
- Ocular surgery within 3 months
Key Trial Info
Start Date :
June 1 2005
Trial Type :
INTERVENTIONAL
End Date :
September 1 2006
Estimated Enrollment :
240 Patients enrolled
Trial Details
Trial ID
NCT00219596
Start Date
June 1 2005
End Date
September 1 2006
Last Update
February 18 2021
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Beijing, Beijing Municipality, China, 100034
2
Pfizer Investigational Site
Beijing, Beijing Municipality, China, 100730
3
Pfizer Investigational Site
Guangzhou, Guangdong, China, 510060
4
Pfizer Investigational Site
Shanghai, Shanghai Municipality, China, 200092